Arvinas, Inc. (NASDAQ: ARVN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.26 | Insider Own | 15.34% | Shs Outstand | 64.52M | Perf Week | 0.00% |
| Market Cap | 518.11M | Forward P/E | - | EPS next Y | -3.44 | Insider Trans | -1.07% | Shs Float | 55.87M | Perf Month | -2.07% |
| Enterprise Value | 439.41M | PEG | 0.02 | EPS next Q | - | Inst Own | - | Short Float | 7.12% | Perf Quarter | -18.89% |
| Income | -223.10M | P/S | 5.80 | EPS this Y | 13.65% | Inst Trans | - | Short Ratio | 4.82 | Perf Half Y | -39.99% |
| Sales | 89.40M | P/B | 1.33 | EPS next Y | -22.28% | ROA | -34.18% | Short Interest | 3.98M | Perf YTD | -32.29% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -44.39% | 52W High | 14.56 -44.66% | Perf Year | 5.94% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -46.80% | 52W Low | 6.08 32.51% | Perf 3Y | -63.96% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 26.15% 58.85% | Gross Margin | 97.43% | Volatility | 3.29% 3.82% | Perf 5Y | -91.59% |
| Dividend TTM | - | EV/Sales | 4.92 | EPS Y/Y TTM | -19.86% | Oper. Margin | -279.31% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.44 | Sales Y/Y TTM | - | Profit Margin | -247.54% | RSI (14) | 44.68 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.44 | EPS Q/Q | -178.95% | SMA20 | -2.52% | Beta | 1.68 | Target Price | 14.75 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | -91.53% | SMA50 | -1.23% | Rel Volume | 0.84 | Prev Close | 8.03 |
| Employees | 246 | LT Debt/Eq | 0.02 | Earnings | Aug 04 | SMA200 | -24.54% | Avg Volume | 820.66K | Price | 8.06 |
| IPO Date | Sep 27, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.56% -6.09% | Net Debt/EBITDA | 0.36 | Volume | 687,894 | Change | 0.37% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-13-26 | Reiterated | BTIG | Buy | $14 → $18 |
| May-13-26 | Reiterated | Barclays | Overweight | $18 → $20 |
| Mar-18-26 | Reiterated | Truist Financial | Hold | $11 → $10 |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy | |
| Dec-17-25 | Reiterated | Barclays | Overweight | $16 → $18 |
| Oct-30-25 | Reiterated | BTIG | Buy | $10 → $14 |
| Oct-15-25 | Downgrade | Goldman Sachs | Neutral → Sell | $6.00 |
| Oct-07-25 | Reiterated | Piper Sandler | Overweight | $14 → $16 |
| Sep-18-25 | Reiterated | BTIG | Buy | $16 → $10 |
| Sep-18-25 | Reiterated | Stephens & Co. | Overweight | $14 |
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 263 | 263 | 79 | 131 | 54 | 26 | 43 | 14 | 8 | |
| Cost of Goods Sold Incl. D&A | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 257 | 263 | 79 | 131 | 54 | 26 | 43 | 14 | 8 | |
| Selling, General and Administrative Excl. Other | 89 | 165 | 100 | 80 | 62 | 38 | 27 | 13 | 4 | |
| Research and Development | 283 | 348 | 380 | 315 | 180 | 108 | 67 | 45 | 29 | |
| Other Operating Expense | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | -1 | |
| Operating Income | -115 | -250 | -401 | -263 | -188 | -121 | -52 | -44 | -25 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 34 | 52 | 35 | 2 | -2 | 2 | -19 | 2 | 1 | |
| Net Income Before Taxes | -80 | -198 | -366 | -262 | -191 | -119 | -70 | -41 | -24 | |
| Income Taxes | 0 | 1 | 1 | 21 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -81 | -199 | -367 | -282 | -191 | -119 | -70 | -41 | -24 | |
| Net Income From Continuing Operations | -81 | -199 | -367 | -282 | -191 | -119 | -70 | -41 | -24 | |
| Net Income | -81 | -199 | -367 | -282 | -191 | -119 | -70 | -41 | -24 | |
| EPS (Recurring) | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | |
| EPS (Basic, Before Extraordinaries) | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | |
| EPS (Diluted) | -1.28 | -2.77 | -6.62 | -5.31 | -3.82 | -3.02 | -1.89 | -1.31 | -1.38 | |
| EBITDA | -75 | -192 | -360 | -253 | -185 | -118 | -68 | -41 | -24 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.93 | 5.25 | 29.18 | 13.84 | 76.06 | 130.66 | 31.53 | 29.37 | — | |
| Gross Margin | 97.72 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Operating Margin | -43.73 | -95.06 | -507.59 | -200.76 | -348.15 | -465.38 | -120.93 | -314.29 | -312.50 | |
| Net Margin | -30.80 | -75.67 | -464.56 | -215.27 | -353.70 | -457.69 | -162.79 | -292.86 | -300.00 | |
| Shares Outstanding | 65 | 72 | 56 | 53 | 50 | 40 | 33 | 32 | 21 | |
| Market Capitalization | 771 | 1,380 | 2,305 | 1,813 | 4,107 | 3,397 | 1,356 | 411 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Saik Andrew | Chief Financial Officer | Jun 24 '26 | Sale | 8.16 | 5,696 | 46,474 | 187,432 | Jun 24 |
| Cacace Angela M | Chief Scientific Officer | Jun 17 '26 | Sale | 7.59 | 2,576 | 19,565 | 180,390 | Jun 18 |
| Teel Randy | President and CEO | May 21 '26 | Sale | 9.04 | 2,209 | 19,962 | 285,009 | May 22 |
| Cacace Angela M | Chief Scientific Officer | May 11 '26 | Sale | 9.94 | 9,657 | 95,965 | 182,966 | May 13 |
| Berkowitz Noah | Chief Medical Officer | May 11 '26 | Sale | 9.94 | 11,108 | 110,385 | 191,395 | May 13 |
| Teel Randy | President and CEO | May 11 '26 | Sale | 9.94 | 9,657 | 95,965 | 287,218 | May 13 |
| Saik Andrew | Chief Financial Officer | May 11 '26 | Sale | 9.94 | 11,139 | 110,693 | 193,128 | May 13 |
| Loomis David K | VP, Chief Accounting Officer | May 11 '26 | Sale | 9.94 | 1,919 | 19,070 | 40,193 | May 13 |
| Berkowitz Noah | Chief Medical Officer | Mar 18 '26 | Sale | 11.10 | 6,435 | 71,431 | 202,503 | Mar 19 |
| Morrison Briggs | Director | Mar 06 '26 | Buy | 13.40 | 20,000 | 268,070 | 96,021 | Mar 09 |
| Houston John G | Director | Feb 27 '26 | Sale | 13.21 | 35,297 | 466,153 | 1,122,183 | Mar 02 |
| Loomis David K | Chief Accounting Officer | Feb 23 '26 | Sale | 12.16 | 1,108 | 13,473 | 29,692 | Feb 25 |
| Cacace Angela M | Chief Scientific Officer | Feb 23 '26 | Sale | 12.16 | 3,609 | 43,885 | 147,623 | Feb 25 |
| Teel Randy | President and CEO | Feb 23 '26 | Sale | 12.16 | 4,786 | 58,198 | 149,696 | Feb 25 |
| Teel Randy | President and CEO | Feb 13 '26 | Sale | 11.89 | 4,403 | 52,352 | 154,482 | Feb 18 |